TN2011000051A1 - Pyrrolidin-2-ones as hdm2 ligands - Google Patents
Pyrrolidin-2-ones as hdm2 ligandsInfo
- Publication number
- TN2011000051A1 TN2011000051A1 TN2011000051A TN2011000051A TN2011000051A1 TN 2011000051 A1 TN2011000051 A1 TN 2011000051A1 TN 2011000051 A TN2011000051 A TN 2011000051A TN 2011000051 A TN2011000051 A TN 2011000051A TN 2011000051 A1 TN2011000051 A1 TN 2011000051A1
- Authority
- TN
- Tunisia
- Prior art keywords
- formula
- compounds
- pyrrolidin
- ones
- disease
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical class O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102100032257 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 abstract 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 abstract 1
- 208000034486 Multi-organ failure Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 239000003183 carcinogenic agent Substances 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides compounds of formula (I) or (Ia) which are ligands binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy and prevention. Compounds of formula (I) or (Ia) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events and heart valvular degenerative disease. Moreover, compounds of formula (I) or (Ia) can be used to decrease the side effects from cytotoxic cancer agents, radiation and to treat viral infections.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2009/006670 WO2010028862A1 (en) | 2008-09-15 | 2009-09-15 | Pyrrolidin-2-ones as hdm2 ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2011000051A1 true TN2011000051A1 (en) | 2012-09-05 |
Family
ID=55024365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TN2011000051A TN2011000051A1 (en) | 2009-09-15 | 2011-01-28 | Pyrrolidin-2-ones as hdm2 ligands |
Country Status (1)
| Country | Link |
|---|---|
| TN (1) | TN2011000051A1 (en) |
-
2011
- 2011-01-28 TN TN2011000051A patent/TN2011000051A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008034039A3 (en) | Novel tetrahydro-isoquinolines | |
| EA201100483A1 (en) | NEW PYRROLIDIN-2-ONE AS HDM2 LIGANDS | |
| ZA201906269B (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| CR20240003A (en) | Novel therapeutic delivery moieties and uses thereof | |
| WO2008128038A3 (en) | Methods and compositions for treating cardiac dysfunctions | |
| PH12016502132A1 (en) | Aryl-or heteroaryl-substituted benzene compounds | |
| DOP2014000058A (en) | 3- PYRMIDIN- 4- IL- OXAZOLIDIN- 2- WAVES AS INHIBITORS OF THE MUTANT HDI | |
| MX346147B (en) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use. | |
| PH12013500011A1 (en) | Napht-2-ylacetic acid derivatives to treat aids | |
| UA105018C2 (en) | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition | |
| MX368305B (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof. | |
| PH12015500186A1 (en) | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib | |
| EA201391644A1 (en) | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS FOR THEIR RECEPTION AND APPLICATION | |
| MX2013004329A (en) | Substituted 6-amino-nicotinamides as kcnq2/3 modulators. | |
| MX2013011691A (en) | Inhibitors of viral replication, their process of preparation and their therapeutical uses. | |
| MX336051B (en) | Diarylacetylene hydrazide containing tyrosine kinase inhibitors. | |
| GB201001602D0 (en) | Oligopeptidic compounds and uses therof | |
| GB2511685A (en) | Muscarinic m1 receptor agonists | |
| MY179527A (en) | Catecholamine derivatives useful for the treatment of parkinson's disease | |
| PH12014502623A1 (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
| PH12020500666A1 (en) | Pladienolide compounds and their use | |
| MX345695B (en) | Heterocyclocarbonylaminothiazoles, cosmetic or dermatological preparations containing said heterocyclocarbonylaminothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin. | |
| MX342119B (en) | Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators. | |
| MX2010000223A (en) | Novel triazine compounds for treatment of cancer. | |
| NZ780840A (en) | Chiral indole compounds and their use |